State Street discloses 5.2% PTC Therapeutics (PTCT) stake in Schedule 13G

Rhea-AI Filing Summary

State Street Corporation has reported a significant passive stake in PTC Therapeutics, Inc.. As of December 31, 2025, State Street beneficially owned 4,206,126 shares of PTC Therapeutics common stock, representing 5.2% of the outstanding class.

State Street reports no sole voting or dispositive power, with 3,973,329 shares subject to shared voting power and 4,206,126 shares subject to shared dispositive power, held through investment management subsidiaries. It certifies the holdings are in the ordinary course of business and not for the purpose of influencing control of PTC Therapeutics.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

PTC THERAPEUTICS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

69366J200

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 69366J200

1

Names of Reporting Persons

STATE STREET CORPORATION

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MASSACHUSETTS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,973,329.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,206,126.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,206,126.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.2 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: PTC THERAPEUTICS INC
(b)	Address of issuer's principal executive offices: 100 CORPORATE COURT, SOUTH PLAINFIELD, NEW JERSEY, 07080
Item 2.
(a)	Name of person filing: STATE STREET CORPORATION;
(b)	Address or principal business office or, if none, residence: ONE CONGRESS STREET, SUITE 1, BOSTON MA 02114, UNITED STATES
(c)	Citizenship: MA
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 69366J200
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 4206126.00
(b)	Percent of class: 5.2 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 3,973,329
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 4,206,126
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. NOT APPLICABLE
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. SSGA FUNDS MANAGEMENT, INC. (IA);STATE STREET GLOBAL ADVISORS EUROPE LIMITED (IA);STATE STREET GLOBAL ADVISORS LIMITED (IA);STATE STREET GLOBAL ADVISORS TRUST COMPANY (IA);STATE STREET GLOBAL ADVISORS, LTD. (IA);
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. NOT APPLICABLE
Item 9.	Notice of Dissolution of Group.
	Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5. NOT APPLICABLE

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

STATE STREET CORPORATION

Signature:	ELIZABETH SCHAEFER
Name/Title:	SENIOR VICE PRESIDENT, CHIEF ACCOUNTING OFFICER
Date:	02/09/2026

FAQ

What stake in PTC Therapeutics (PTCT) does State Street report on this Schedule 13G?

State Street reports beneficial ownership of 4,206,126 shares of PTC Therapeutics common stock, representing 5.2% of the class as of December 31, 2025. This filing reflects State Street’s role as an institutional investment manager.

Does State Street have voting and dispositive power over its PTCT shares?

State Street reports no sole voting or dispositive power over PTCT shares. It has shared voting power over 3,973,329 shares and shared dispositive power over 4,206,126 shares, primarily through its investment advisory and trust company subsidiaries.

Is State Street’s 5.2% position in PTC Therapeutics intended to influence control?

State Street certifies the PTCT securities were acquired and are held in the ordinary course of business and not for changing or influencing control of PTC Therapeutics. The stake is reported on a Schedule 13G, typically used for passive institutional holdings.

Which State Street subsidiaries are associated with the PTCT holdings in this Schedule 13G?

The filing identifies several investment management subsidiaries, including SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, State Street Global Advisors Trust Company, and State Street Global Advisors, Ltd. as related entities.

Why was this Schedule 13G for PTC Therapeutics (PTCT) filed as of December 31, 2025?

The Schedule 13G reflects State Street’s beneficial ownership position as of December 31, 2025, when its holdings reached 5.2% of PTCT’s common stock. Crossing the five percent threshold triggers a requirement to report under beneficial ownership rules.

Who signed the Schedule 13G reporting State Street’s stake in PTC Therapeutics?

The Schedule 13G was signed by Elizabeth Schaefer, identified as Senior Vice President and Chief Accounting Officer, on February 9, 2026. The signature certifies that the information provided is true, complete, and correct to the best of her knowledge.